USCOM LIMITED — AGM Information 2016

Nov 29, 2016

2016 Annual General Meeting Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Uscom Executive Chairman/CEO

==> picture [960 x 43] intentionally omitted <==

==> picture [960 x 35] intentionally omitted <==

Uscom Limited 2016 ANNUAL GENERAL MEETING

==> picture [960 x 35] intentionally omitted <==

Introduction

Board of Directors: Prof Rob Phillips (Executive) Ms Sheena Jack (Non-executive) Mr Christian Bernecker (Non-executive) Mr David He (Non-executive) Company Secretary – Mr Brett Crowley BDO Auditors – Mr Gareth Few

==> picture [960 x 35] intentionally omitted <==

Agenda

• Quorum / Open meeting

• Chairman’s Welcome, Introduction of Board Members

• Chairman’s Presentation

• Results and operations 2016

• Strategy 2017

• Notice of Meeting – Taken as Read

• Consideration of Reports

• Business – Resolutions 1 - 6

• Close of Meeting

• Question and Answers

==> picture [960 x 35] intentionally omitted <==

Executive Chairman’s Report

Associate Professor Rob Phillips PhD(Med), MPhil(Med), FASE, DMU(Cardiol) Executive Chairman, Chief Executive Officer, Head Clinical Science

==> picture [960 x 35] intentionally omitted <==

Uscom - 2016

“Growing as planned!”

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

Uscom - Mission

"Uscom is a leading innovator in medical devices, developing new technologies to address the challenges of global disease and health care. Uscom is driven by a commercial ambition to become a leader in global health business.”

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

2016 Results

Growth:

Record revenue, sales, cash, share price, cap value (+44 to114%) And investment:

Transformational $65m 5yr China agreement

Acquired and consolidated Thor laboratories into Uscom One off investments:

acquisition and integration (≈$1m)

BP+ and SpiroSonic prepared for revenue in 2017 (≈$0.5m) global corporate model established

Approaching profitability with two new device series for sale in 2017

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

2016 Results

Total Revenue

Receipts from Customers

==> picture [885 x 274] intentionally omitted <==

----- Start of picture text -----

$3,500,000
2,563,145
2,500,000
$2,936,504
$3,000,000
2,000,000
$2,500,000
$2,039,426
$2,000,000
1,500,000
1,321,080
$
$1,500,000 $1,377,716
1,000,000
$1,010,942 829,424
$1,000,000 $864,099
621,253
500,000
$500,000
$0 -
2012 2013 2014 2015 2016 2013 2014 2015 2016
----- End of picture text -----

Total revenue +44% to $2.94m +43% CAGR for 3 years

Receipts from Customers +94% to $2.56m +60% CAGR for 3 years

• Estimate

==> picture [960 x 35] intentionally omitted <==

2016 Results

Quarterly Total Revenue

Quarterly Cash Receipts

==> picture [440 x 273] intentionally omitted <==

----- Start of picture text -----

900000
800000
700000
600000
500000
$
400000
300000
200000
100000
0
Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16 Q3 16 Q4 16
----- End of picture text -----

==> picture [453 x 283] intentionally omitted <==

----- Start of picture text -----

700,000
600,000
500,000
400,000
$
300,000
200,000
100,000
0
Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16 Q3 16 Q4 16
----- End of picture text -----

2016 – Total Revenue and Cash Receipts CAGR 44% and 94% CAGR 3 years

• Estimate

==> picture [960 x 35] intentionally omitted <==

2016 Results

Cash, Equity and Assets

==> picture [589 x 290] intentionally omitted <==

----- Start of picture text -----

6,000,000 5,711,746
4,937,991
5,000,000
4,000,000
2,936,355
$ 3,000,000 2,839,773 2015
2016
2,288,661
2,000,000
1,290,796
992,796
1,000,000
526,317
0
Cash Cash Spend Equity Assets
----- End of picture text -----

A year of investment

• Estimate

==> picture [960 x 35] intentionally omitted <==

Announcements

2015 July September November 2016 January	• USA FDA Clearance for Thor Ultrasonic Spirometers • Uscom Completes Thor Acquisition • Uscom Establishes UK Subsidiary • USCOM can Replace Cardiac Catheters in Children • New SpiroSonic Series of Asthma Products • Non-invasive BP+ Equal to Catheters for Central Blood Pressure in Children

==> picture [960 x 35] intentionally omitted <==

Announcements

2016 February March May June

• Uscom Customer Receipts Up 72% In First Half • Uscom BP+ Contracted Into UK NHS Supply Chain • Former J&J Asia Executive Appointed to Uscom Board • Paediatric sepsis mortality reduced 46% with USCOM use: 11. New Thai critical care study • Uscom may improve outcomes and reduce cost in surgery • Uscom appoints new Company Secretary • Uscom Oversubscribed PP for Strategic Investment • New Uscom BP+ Distributor in Vietnam • Uscom agreement with CIIC Shanghai

==> picture [960 x 35] intentionally omitted <==

Announcements

• 2016 •

• July New US Uscom BP+ Patent • Additional Uscom BP+ US Patent

• •

• October Uscom Budapest Revenue up 48% pa • Paediatric Sepsis Outcomes Improved With USCOM

• • CE Mark for New Uscom Asthma and COPD Devices

• •

• November Uscom CEO Appointed to Govt China Initiative • Uscom Awarded Euro Grant for Lung Cancer Diagnostic

Busy growing

==> picture [960 x 35] intentionally omitted <==

Building Great Brands

==> picture [127 x 32] intentionally omitted <==

==> picture [302 x 99] intentionally omitted <==

==> picture [167 x 98] intentionally omitted <==

Uscom – devices the experts use

==> picture [960 x 35] intentionally omitted <==

Building Great Products

==> picture [325 x 284] intentionally omitted <==

==> picture [77 x 137] intentionally omitted <==

==> picture [178 x 182] intentionally omitted <==

Uscom – devices the experts use

==> picture [960 x 35] intentionally omitted <==

Building New Markets

Telemonitoring asthma and COPD

Digital ultrasonic spirometers Wireless connectivity Proprietary apps and software Diagnostic and therapeutic monitoring Leading pulmonary monitors in eHealth 450 sold into the US (2016) Growing global market

==> picture [189 x 166] intentionally omitted <==

==> picture [136 x 150] intentionally omitted <==

==> picture [77 x 137] intentionally omitted <==

==> picture [40 x 47] intentionally omitted <==

==> picture [41 x 48] intentionally omitted <==

Uscom Phone App

Uscom digital spirometers

Bringing patients and clinicians together – The digital eHealth future

==> picture [215 x 153] intentionally omitted <==

==> picture [215 x 164] intentionally omitted <==

SpiroReporter software

==> picture [960 x 35] intentionally omitted <==

Meeting Global Clinical Needs

==> picture [487 x 390] intentionally omitted <==

Uscom addresses conditions responsible for 80% of the leading causes of death worldwide (WHO criteria). Heart failure, sepsis, hypertension, asthma, COPD.

http://www.who.int/mediacentre/factsheets/fs310/en/ - accessed 4[th] Aug 2016

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

Changing outcomes

36 new publications

Outcomes Changes

==> picture [603 x 279] intentionally omitted <==

----- Start of picture text -----

120
100 100 100 100
100
80
66
% 60 ACCM+echo
50
ACCM+echo + NE/USCOM
42
40
25
20
0
Fluid - 6hrs Fluid Bal 24hrs Invasive Ventilation days PICU days
----- End of picture text -----

Changing the lives of children with septic shock in India

Ranjit S, Natraj R, Kandath SK, Kissoon N, Ramakrishnan B, Marik P. Early nor-epinephrine decreased fluid and ventilatory requirements in paediatric septic shock. Indian J Crit Care Med 2016;20:561-9.

==> picture [960 x 35] intentionally omitted <==

New patents

Two new US BP+ patents

==> picture [112 x 112] intentionally omitted <==

==> picture [460 x 183] intentionally omitted <==

==> picture [141 x 140] intentionally omitted <==

1. Central algorithms BP+

Notice of Allowance from the United States Patent and Trademarks Office for the patent covering the central algorithms in the Uscom BP+ suprasystolic oscillometric central blood pressure monitor. The Patent has a priority date of 13[th] May 2009.

2. Method and apparatus BP+ Notice of Allowance from the United States Patent and Trademarks Office for a patent covering the method and apparatus for producing central pressure waveforms in an oscillometric blood pressure system. The patent has a priority date of 12th July 2009.

IP – Protecting our commercial future

==> picture [960 x 35] intentionally omitted <==

Global manufacturing

To meet demand.

Currently

Future

 USCOM 1A and BP+ in Sydney

 SpiroSonic and BP+ in Hungary

 SpiroSonic in Hungary

==> picture [223 x 162] intentionally omitted <==

==> picture [123 x 161] intentionally omitted <==

==> picture [217 x 160] intentionally omitted <==

==> picture [233 x 160] intentionally omitted <==

==> picture [960 x 35] intentionally omitted <==

2016 Results

" Investors can review Uscom’s progress in 2016 with satisfaction and look forward to the rewards of 2017 and beyond. Uscom has invested in the future, and investors will share in the profits of this investment as we continue to meet our milestones.”

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

2017 milestones

More products - Global launch BP+ (+2) Global launch SpiroSonic products (+7) More Revenue - Continue USCOM sales growth Global pricing More and better distribution Cross distribute USCOM/BP+/SpiroSonic Reimbursement drive Global operations – Grow US, UK and Budapest operations Grow China Market value - Grow company fundamentals and shareholder value Uscom has a history of meeting our milestones

More products - More Revenue -

==> picture [960 x 35] intentionally omitted <==

China partnerships

State funded growth

CIIC to import $65m of Uscom devices and support regulatory over 5 yrs

Health spend from 6-12% of GDP

1.35b population in 31 provinces Revenue targets in China $20m

Uscom positioning to grow with China - $20m pa revenue target

==> picture [960 x 35] intentionally omitted <==

Worldwide regulatory

The path to global markets

Uscom has established in house skills in regulatory approval of medical devices

• Europe - CE

• China – CFDA

• USA - FDA 510k

• Multiple small jurisdictions (TGA etc.)

CE is also used for other countries as a basis for registration

==> picture [382 x 244] intentionally omitted <==

==> picture [960 x 35] intentionally omitted <==

Regulatory

Jurisdictions

Products 2016 2017 CFDA CE FDA CFDA CE FDA 1 USCOM 1A ✓ ✓ ✓ ✓ ✓ ✓ 2 Uscom BP+ ★ ★ ★ ★ ★ ★ 3 Uscom BP+Reporter ★ ★ ★ ★ ★ ★ 4 SpiroSonic Flo ★ ★ ★ ★ ✓ ★ 5 Smart ★ ★ ★ ★ ✓ ★ 6 Mobile ★ ★ ★ ★ ✓ ★ 7 Pro ★ ★ ★ ★ ✓ ★ 8 SpiroReporter ★ ★ ★ ★ ✓ ★ 9 tSpiro ★ ★ ★ ★ ✓ ★ 10 SpiroApp ★ ★ ★ ★ ✓ ★	Products 2016 2017 CFDA CE FDA CFDA CE FDA 1 USCOM 1A ✓ ✓ ✓ ✓ ✓ ✓ 2 Uscom BP+ ★ ★ ★ ★ ★ ★ 3 Uscom BP+Reporter ★ ★ ★ ★ ★ ★ 4 SpiroSonic Flo ★ ★ ★ ★ ✓ ★ 5 Smart ★ ★ ★ ★ ✓ ★ 6 Mobile ★ ★ ★ ★ ✓ ★ 7 Pro ★ ★ ★ ★ ✓ ★ 8 SpiroReporter ★ ★ ★ ★ ✓ ★ 9 tSpiro ★ ★ ★ ★ ✓ ★ 10 SpiroApp ★ ★ ★ ★ ✓ ★	Products 2016 2017 CFDA CE FDA CFDA CE FDA 1 USCOM 1A ✓ ✓ ✓ ✓ ✓ ✓ 2 Uscom BP+ ★ ★ ★ ★ ★ ★ 3 Uscom BP+Reporter ★ ★ ★ ★ ★ ★ 4 SpiroSonic Flo ★ ★ ★ ★ ✓ ★ 5 Smart ★ ★ ★ ★ ✓ ★ 6 Mobile ★ ★ ★ ★ ✓ ★ 7 Pro ★ ★ ★ ★ ✓ ★ 8 SpiroReporter ★ ★ ★ ★ ✓ ★ 9 tSpiro ★ ★ ★ ★ ✓ ★ 10 SpiroApp ★ ★ ★ ★ ✓ ★
Products	2016	2017
	CFDA CE FDA	CFDA CE FDA
1 USCOM 1A	✓ ✓ ✓	✓ ✓ ✓
2 Uscom BP+	★ ★ ★	★ ★ ★
3 Uscom BP+Reporter	★ ★ ★	★ ★ ★
4 SpiroSonic Flo	★ ★ ★	★ ✓ ★
5 Smart	★ ★ ★	★ ✓ ★
6 Mobile	★ ★ ★	★ ✓ ★
7 Pro	★ ★ ★	★ ✓ ★
8 SpiroReporter	★ ★ ★	★ ✓ ★
9 tSpiro	★ ★ ★	★ ✓ ★
10 SpiroApp	★ ★ ★	★ ✓ ★

★ In preparation/submitted ★ Expected ✓ Achieved

==> picture [960 x 35] intentionally omitted <==

New distribution

Medica – Taking Uscom products to the world

Three leading product lines

Global distribution

130,000 Delegates

5,000 Exhibitors

New distributors in advance of regulatory approvals

Distribution Agreements

==> picture [343 x 240] intentionally omitted <==

----- Start of picture text -----

60
55
50
42
40
36
30
23
20
12
10
0
2013 2014 2015 2016 2017
----- End of picture text -----*

==> picture [205 x 202] intentionally omitted <==

Distributors are feet on the ground - revenue

*Aniticipated

==> picture [960 x 35] intentionally omitted <==

Three global brands

==> picture [266 x 87] intentionally omitted <==

==> picture [167 x 98] intentionally omitted <==

Science – Manufacture – Regulatory – Market - Revenue

Three revenue streams

==> picture [960 x 35] intentionally omitted <==

Revenue model

Total Revenue

==> picture [580 x 369] intentionally omitted <==

----- Start of picture text -----

20,000,000
17,500,000
15,000,000
12,500,000
$ 10,000,000
7,500,000
5,000,000
2,500,000
0
2015 2016 2017 2018 2019 2020
$20m revenue by 2020 = 5 year CAGR of 58%
----- End of picture text -----

==> picture [223 x 74] intentionally omitted <==

==> picture [139 x 82] intentionally omitted <==

==> picture [960 x 35] intentionally omitted <==

Uscom news!

Uscom receives European Award to Develop Lung Cancer Diagnostic

==> picture [203 x 119] intentionally omitted <==

==> picture [115 x 151] intentionally omitted <==

==> picture [114 x 113] intentionally omitted <==

“To develop a simple breath test device for early diagnosis of lung cancer and a wide range of viral, microbial, neoplastic (cancer) and genetic diseases.”

Total 2.7m Euro (AU$3.8m) 3 year grant from The Hungarian National Research, Development and Innovation Office. 300k Euro (AU$427k) for Uscom in the first stage, in collaboration with the Material Sciences Department of the Hungarian Academy of Science, and the Medical School of the Semmelweis University in Budapest. Uscom owns all developed IP, with first right of refusal to commercialise new project developed IP

Uscom’s global reputation for excellence in science

==> picture [960 x 35] intentionally omitted <==

Uscom - 2017

"Uscom has acquired global assets to ensure reliable revenue growth and long term profitability. Our strategy is to efficiently deliver the devices we have developed into global markets.

Establish a culture of profitable performance and future shareholder dividends.”

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

Uscom - 2017

“Continuing to grow as planned”

Uscom – Medical devices the experts use

==> picture [960 x 38] intentionally omitted <==

Questions

2016 Annual General Meeting Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Uscom Executive Chairman/CEO

==> picture [960 x 43] intentionally omitted <==